{
  "report_rows": [
    {
      "kpi": "Adjusted EPS (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$0.91 vs. cons $0.90",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Organic sales growth (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~3.3% vs. cons 3.0%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted gross-margin expansion (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~60 bps vs. cons 50 bps",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Adjusted EPS (FY 2026 midpoint)",
      "prediction": "BETTER",
      "answer": "guide ~$3.76 vs. cons $3.74 (FY 2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Organic sales growth (FY 2026 midpoint)",
      "prediction": "UNCHANGED",
      "answer": "guide ~3.5% vs. cons 3.5% (FY 2026)",
      "confidence": "HIGH"
    },
    {
      "kpi": "Adjusted gross-margin expansion (FY 2026)",
      "prediction": "UNCHANGED",
      "answer": "guide ~100 bps vs. cons 100 bps (FY 2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted EPS (Q3 2026)",
      "prediction": "LOWER",
      "answer": "guide ~$0.91 vs. cons $0.92 (Q3 2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 0.8,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 0.2,
  "day5_path": "FADE",
  "day5_rationale": "Day-1 residual ~+0.8% vs. five-day cumulative residual ~+0.2%: modest Q2 beats support the initial move, but unchanged full-year guidance and a Q3 EPS guide about $0.01 below consensus limit estimate revisions and cause most of the gain to fade.",
  "day5_confidence": "MEDIUM"
}